Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Travel, energy stocks drag UK shares lower, weighed by coronavirus fears

10/26/2020 | 05:26am EST

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* Surge in coronavirus cases dents mood

* EU negotiator Barnier extends London visit for Brexit talks

* AstraZeneca gains on positive COVID-19 vaccine update

* Coca-Cola European Partners rise on buyout offer

* FTSE 100 down 1.2%, FTSE 250 drops 1.4%

Oct 26 (Reuters) - London stocks closed sharply lower on Monday, weighed by travel and energy stocks, while a resurgence in novel coronavirus cases stoked fears of a faltering economic recovery and dragged down European markets. After rising nearly 0.1% in morning trade, the blue-chip FTSE 100 index fell 1.2%, led by declines in travel and leisure, personal goods makers, retailers and aero stocks.

Energy and mining weighed the most on the index due to weaker commodity prices.

The domestically focussed mid-cap FTSE 250 index lost 1.4% even as European Union chief negotiator Michel Barnier and his team extended their London visit until Wednesday to try and clinch a Brexit trade deal.

European markets were weighed down by a plunge in tech major SAP, an impasse over the U.S. stimulus package and fears that a resurgence in coronavirus cases could hamper a global economic recovery as governments tighten restrictions on businesses and social activity.

"The fact that (more) countries are now reining in the freedom of people to move around is going to have a detrimental impact on the actual overall activity level in the economy", said Saxo Bank chief investment officer Steen Jakobsen.

"UK is even more challenged due to the COVID-19 close-down and Brexit."

After a stimulus-backed rally from pandemic lows, the FTSE 100 has been trading in tight ranges since June due to Brexit-related uncertainty and concerns over coronavirus curbs.

In a bright spot, AstraZeneca Plc rose 1.7% after the drugmaker resumed the U.S. trial of its experimental COVID-19 vaccine that is being developed with the University of Oxford, and said it produced a similar immune response in both older and younger adults.

The wider healthcare index added 1%.

Educational publisher Pearson Plc added 3% after UBS upgraded the stock to a "buy" rating.

Coca-Cola European Partners (CCEP) rose 0.3% after the soft drink bottler made a buyout offer of $6.6 billion for its Australian peer Coca-Cola Amatil Ltd. (Reporting by Devik Jain in Bengaluru; editing by Aditya Soni and Bernadette Baum)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.44% 7592 Delayed Quote.3.66%
COCA-COLA AMATIL LIMITED -0.23% 12.95 End-of-day quote.0.15%
EURO / BRITISH POUND (EUR/GBP) 0.08% 0.88866 Delayed Quote.-0.60%
MSCI UNITED KINGDOM (STRD, UHD) -1.67% 1069.544 Real-time Quote.5.50%
PEARSON PLC -0.24% 678 Delayed Quote.-0.35%
SAP SE -0.65% 103.52 Delayed Quote.-3.45%
All news about ASTRAZENECA PLC
07:06aTHE LATEST : Biden elevates science adviser to Cabinet level
AQ
04:23aASTRAZENECA : India starts world's largest COVID-19 vaccination drive
AQ
01/15MODERNA : WHO sees poorer countries getting first COVID vaccines this quarter
RE
01/15SINOVAC BIOTECH : Brazil airlifts emergency oxygen into pandemic-struck state, v..
RE
01/15ASTRAZENECA : Deutsche Bank Initiates Coverage on AstraZeneca With Buy Rating
MT
01/15European ADRs Move Sharply Lower in Friday Trading
MT
01/15South Africa's mining industry to support COVID-19 vaccine rollout
RE
01/15ASTRAZENECA : Nepal clears AstraZeneca vaccine for emergency use
AQ
01/15ASTRAZENECA : Buy rating from Deutsche Bank
MD
01/15ASTRAZENECA : Obtains European Approval for Imfinzi's Expanded Dosing Option
MT
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,0x
Yield 2020 2,73%
Capitalization 135 B 135 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,14 $
Spread / Highest target 51,3%
Spread / Average Target 22,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC3.66%135 464
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993